Prediction of cancer drugs by chemical-chemical interactions

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lu, Jing ^a   Huang, Guohua ^b,c   Li, Hai Peng ^d   Feng, Kai Yan ^e   Chen, Lei ^f   Zheng, Ming Yue ^g   Cai, Yu Dong ^b  

^a YANTAI UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY   (China)

^c SHAOYANG UNIVERSITY   (China)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^e BGI SHENZHEN   (China)

^f SHANGHAI MARITIME UNIVERSITY   (China)

^g SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; DACTINOMYCIN; DIETHYLSTILBESTROL; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GEFITINIB; GEMCITABINE; GOSERELIN; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MITOMYCIN; MITOTANE; NAVELBINE; PROCARBAZINE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THIOTEPA; UNINDEXED DRUG;

ACCURACY; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; INTERMETHOD COMPARISON; JACKKNIFE TEST; MATHEMATICAL MODEL; NEOPLASM; PREDICTION; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; INFORMATICS; MODELS, THEORETICAL; NEOPLASMS;

EID: 84894632821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087791     Document Type: Article

References (135)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Walters WP, Green J, Weiss JR, Murcko MA (2011) What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 54: 6405-6416.
3. Hu L, Huang T, Liu XJ, Cai YD (2011) Predicting protein phenotypes based on protein-protein interaction network. PLoS One 6: e17668.
4. Hu L, Huang T, Shi X, Lu WC, Cai YD, et al. (2011) Predicting functions of proteins in mouse based on weighted protein-protein interaction network and protein hybrid properties. PLoS One 6: e14556.
5. Gao P, Wang QP, Chen L, Huang T (2012) Prediction of human genes' regulatory functions based on proteinprotein interaction network. Protein Pept Lett 19: 910-916.
6. Hu LL, Chen C, Huang T, Cai YD, Chou KC (2011) Predicting biological functions of compounds based on chemical-chemical interactions. PLoS One 6: e29491.
7. Chen L, Zeng WM, Cai YD, Feng KY, Chou KC (2012) Predicting Anatomical Therapeutic Chemical (ATC) Classification of Drugs by Integrating Chemical-Chemical Interactions and Similarities. PLoS ONE 7: e35254.
8. Chen L, Lu J, Zhang J, Feng K-R, Zheng M-Y, et al. (2013) Predicting Chemical Toxicity Effects Based on Chemical-Chemical Interactions. PLoS ONE 8: e56517.
9. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P (2008) STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36: D684-688. (Pubitemid 351149807)
10. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, et al. (2010) STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 38: D552-556.
11. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research 28: 27-30. (Pubitemid 30047706)
12. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic acids research 34: D668-D672.
13. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683. (Pubitemid 39173508)
14. Boguski MS, Mandl KD, Sukhatme VP (2009) Drug discovery. Repurposing with a difference. Science 324: 1394-1395.
15. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621-14626.
16. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76.
17. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3: 96ra77.
18. Cheng F, Liu C, Jiang J, Lu W, Li W, et al. (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8: e1002503.
19. Du P, Li T, Wang X (2011) Recent progress in predicting protein sub-subcellular locations. Expert Review of Proteomics 8: 391-404.
20. Gao YF, Chen L, Cai YD, Feng KY, Huang T, et al. (2012) Predicting Metabolic Pathways of Small Molecules and Enzymes Based on Interaction Information of Chemicals and Proteins. PLoS ONE 7: e45944.
21. Sharan R, Ulitsky I, Shamir R (2007) Network-based prediction of protein function. Molecular systems biology 3: 88.
22. Ng KL, Ciou JS, Huang CH (2010) Prediction of protein functions based on function-function correlation relations. Computers in Biology and Medicine 40: 300-305.
23. AMPAC, Semichem, Inc.: Shawnee, KS 66216.
24. COmprehensive DEscriptors for Structural and Statistical Analysis (CODESSA), Semichem, Inc.: Shawnee, KS 66216.
25. Chen L, Zeng W-M, Cai Y-D, Huang T (2013) Prediction of Metabolic Pathway Using Graph Property, Chemical Functional Group and Chemical Structural Set. Current Bioinformatics 8: 200-207.
26. Georgiou D, Karakasidis T, Nieto J, Torres A (2009) Use of fuzzy clustering technique and matrices to classify amino acids and its impact to Chou's pseudo amino acid composition. Journal of theoretical biology 257: 17-26.
27. Ramani RG, Jacob SG (2013) Prediction of P53 Mutants (Multiple Sites) Transcriptional Activity Based on Structural (2D&3D) Properties. PLoS ONE 8: e55401.
28. Matsuta Y, Ito M, Tohsato Y (2013) ECOH: An Enzyme Commission number predictor using mutual information and a support vector machine. Bioinformatics 29: 365-372.
29. Huang T, Chen L, Cai Y, Chou C (2011) Classification and Analysis of Regulatory Pathways Using Graph Property, Biochemical and Physicochemical Property, and Functional Property. PLoS ONE 6: e25297.
30. Deng M, Zhang K, Mehta S, Chen T, Sun F (2003) Prediction of Protein Function Using Protein-protein Interaction Data. Journal of Computational Biology 10: 947-960. (Pubitemid 38156407)
31. Chua HN, Sung WK, Wong L (2006) Exploiting indirect neighbours and topological weight to predict protein function from protein-protein interactions. Bioinformatics 22: 1623-1630. (Pubitemid 43985296)
32. http://pubs.acs.org/cen/coverstory/83/8325/8325cisplatin.html. (accessed March 26, 2013).
33. http://www.cisplatin.org/. (accessed March 26, 2013).
34. Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39: 8113-8127.
35. Prasad SB, Giri A (1994) Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Indian J Exp Biol 32: 155-162. (Pubitemid 24087649)
36. http://www.drugbank.ca/drugs/DB01181. (accessed March 27, 2013).
37. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, et al. (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99: 1016-1020. (Pubitemid 351997606)
38. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, et al. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29: 4410-4416.
39. http://www.drugbank.ca/drugs/DB01206. (accessed March 27, 2013).
40. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, et al. (1999) Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 13: 395-398.
41. Saba CF, Thamm DH, Vail DM (2007) Combination chemotherapy with Lasparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 21: 127-132.
42. Flory AB, Rassnick KM, Al-Sarraf R, Bailey DB, Balkman CE, et al. (2008) Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 22: 164-171. (Pubitemid 351361467)
43. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, et al. (2006) CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 20: 136-143. (Pubitemid 43219383)
44. Heading KL, Brockley LK, Bennett PF (2011) CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J 89: 109-116.
45. Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6: 386-394. (Pubitemid 40561415)
46. Luton J-P, Cerdas S, Billaud L, Thomas G, Guilhaume B, et al. (1990) Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy. New England Journal of Medicine 322: 1195-1201. (Pubitemid 20137851)
47. Jarabak J, Rice K (1981) Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy. JAMA 246: 1706-1707. (Pubitemid 11015754)
48. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356: 2372-2380. (Pubitemid 46883771)
49. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, et al. (2013) Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 98: 161-171.
50. Swaffar DS, Horstman MG, Jaw JY, Thrall BD, Meadows GG, et al. (1989) Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Cancer Res 49: 2442-2447. (Pubitemid 19125576)
51. http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-12.pdf. (accessed March 27, 2013).
52. Halbsguth TV, Nogova L, Mueller H, Sieniawski M, Eichenauer DA, et al. (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 116: 2026-2032.
53. http://www.drugbank.ca/drugs/DB00853. (accessed March 27, 2013).
54. Reni M, Zaja F, Mason W, Perry J, Mazza E, et al. (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96: 864-867. (Pubitemid 46452291)
55. http://www.drugbank.ca/drugs/DB04572. (accessed March 28, 2013).
56. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, et al. (2007) Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 48: 759-766. (Pubitemid 46605549)
57. Kolb EA, Steinherz PG (2003) A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 17: 1967-1972. (Pubitemid 37322126)
58. http://www.drugbank.ca/drugs/DB00322. (accessed March 29, 2013).
59. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, et al. (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646-1654. (Pubitemid 19272834)
60. Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, et al. (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 51: 1523-1529.
61. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, et al. (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17: 3776-3785.
62. http://www.drugbank.ca/drugs/DB00445. (accessed March 30, 2013).
63. Rummel MJ, Kafer G, Pfreundschuh M, Jager E, Reinhardt U, et al. (1999) Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 10: 183-188. (Pubitemid 29113178)
64. http://www.drugbank.ca/drugs/DB00441. (accessed March 30,2013).
65. http://www.drugbank.ca/drugs/DB00361. (accessed March 30, 2013).
66. Aapro M, Finek J (2012) Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev 38: 120-126.
67. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, et al. (1999) Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10: 397-402. (Pubitemid 29236416)
68. http://www.drugbank.ca/drugs/DB00762. (accessed March 30, 2013).
69. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, et al. (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22: 2849-2855. (Pubitemid 41079903)
70. Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, et al. (2013) Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer 20: 131-136.
71. Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, et al. (2005) Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 56: 487-491. (Pubitemid 41549150)
72. Blum JL (1999) Xeloda in the treatment of metastatic breast cancer. Oncology 57 Suppl 1: 16-20.
73. http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/20896lbl.pdf. (accessed March 30, 2013).
74. Ershler WB (2006) Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11: 325-335.
75. http://www.drugbank.ca/drugs/DB00317. (accessed March 30, 2013).
76. Leibl S, Moinfar F (2005) Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 58: 700-704. (Pubitemid 40956822)
77. http://www.drugbank.ca/drugs/DB00398. (accessed March 30, 2013).
78. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, et al. (2009) Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27: 4274-4280.
79. http://www.drugbank.ca/drugs/DB01229. (accessed March 30, 2013).
80. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA (2003) The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98: 779-788. (Pubitemid 36959275)
81. http://www.drugbank.ca/drugs/DB00851. (accessed March 31, 2013).
82. Baker TR, Piver MS, Caglar H, Piedmonte M (1991) Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 14: 246-250.
83. http://www.drugbank.ca/drugs/DB01268. (accessed March 31, 2013).
84. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, et al. (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816.
85. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, et al. (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 21: 1436-1441.
86. http://www.drugbank.ca/drugs/DB00499. (accessed August 1, 2013).
87. Dimonaco M, Brignardello E, Leonardi L, Gatto V, Gallo M, et al. (1993) The antiandrogen flutamide inhibits growth of mcf-7 human breast-cancer cell-line. Int J Oncol 2: 653-656. (Pubitemid 23132688)
88. http://www.drugbank.ca/drugs/DB00650. (accessed August 21, 2013).
89. Repetto L, Miglietta L, Gardin G, Lanfranco C, Naso C, et al. (1994) Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 30: 133-137. (Pubitemid 24242664)
90. Rivera E, Chang JC, Semiglazov V, Gorbunova V, Manikhas A, et al. (2012) Eniluracil +5-fluorouracil+leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX. pp. Supplement 3.
91. Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, et al. (2009) Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101: 341-349.
92. http://www.drugbank.ca/drugs/DB00544. (accessed August 1, 2013).
93. Takeno A, Tamura S, Miki H, Ono H, Uchiyama C, et al. (2010) [Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy-a case report]. Gan To Kagaku Ryoho 37: 2382-2384.
94. http://www.drugbank.ca/drugs/DB00970. (accessed March 26, 2013).
95. James DH Jr, Hustu O, Wrenn EL Jr, Johnson WW (1966) Childhood malignant tumors. Concurrent chemotherapy with dactinomycin and vincristine sulfate. JAMA 197: 1043-1045.
96. http://www.drugbank.ca/drugs/DB00305. (accessed March 28, 2013).
97. Yu CS, Chiu SI, Ng CS, Chan HH, Tse RK (2008) Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy. Int Ophthalmol 28: 51-54. (Pubitemid 351308684)
98. Sartorelli AC, Booth BA (1965) The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil. Cancer Res 25: 1393-1400.
99. Imai R, Morimoto M (1983) Comparative antitumor activities of 7-N-(phydroxyphenyl) mitomycin C (M-83) and mitomycin C. J Antibiot (Tokyo) 36: 559-565. (Pubitemid 13103005)
100. http://www.drugbank.ca/drugs/DB00773. (accessed March 31, 2013).
101. Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, et al. (1999) Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study. Gynecol Oncol 74: 432-435. (Pubitemid 29439885)
102. Kanazawa K, Moromizato H (1996) [Etoposide (VP-16) in gynecologic malignancy]. Gan To Kagaku Ryoho 23: 1925-1928.
103. Kredentser DC (1991) Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol Oncol 43: 145-148.
104. http://www.drugbank.ca/drugs/DB00255. (accessed in November 7, 2013).
105. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL (1999) Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54: 117-122. (Pubitemid 29295314)
106. http://www.drugbank.ca/drugs/DB00290. (accessed in November 7, 2013).
107. Takeuchi K (1975) A clinical trial of intravenous bleomycin in the treatment of brain tumors. Int J Clin Pharmacol Biopharm 12: 419-426.
108. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, et al. (2011) Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 71: 3753-3762.
109. http://www.drugbank.ca/drugs/DB00307. (accessed in November 8, 2013).
110. Wang Y, Zhang Z, Yao R, Jia D, Wang D, et al. (2006) Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 25: 1320-1329. (Pubitemid 43336460)
111. Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, et al. (2005) The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50: 9-18. (Pubitemid 41297464)
112. http://www.drugbank.ca/drugs/DB00380. (accessed in November 8, 2013).
113. Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, et al. (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59: 541-544. (Pubitemid 41820383)
114. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, et al. (2004) The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine 351: 145-153. (Pubitemid 38886649)
115. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, et al. (2011) The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 47: 1373-1379.
116. http://www.drugbank.ca/drugs/DB00385. (accessed in November 10, 2013).
117. Schwartz HS, Kanter PM (1981) DNA damage by anthracycline drugs in human leukemia cells. Cancer Lett 13: 309-313. (Pubitemid 11012589)
118. Andersen SM, Rosada C, Dagnaes-Hansen F, Laugesen IG, de Darko E, et al. (2010) Topical application of valrubicin has a beneficial effect on developing skin tumors. Carcinogenesis 31: 1483-1490.
119. http://www.drugbank.ca/drugs/DB00399. (accessed in November 8, 2013).
120. Steinman RA, Brufsky AM, Oesterreich S (2012) Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res 14: 213.
121. http://www.drugbank.ca/drugs/DB00642. (accessed in November 8, 2013).
122. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchiano A, et al. (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14: 1543-1548. (Pubitemid 37304611)
123. http://www.drugbank.ca/drugs/DB01185. (accessed in November 10, 2013).
124. Bai GZ, Hara H, Nagai K (1984) Influence of fluoxymesterone on in vitro erythropoiesis affected by leukemic cells. Exp Hematol 12: 171-176. (Pubitemid 14121697)
125. http://www.drugbank.ca/downloads. (accessed in November 10, 2013).
126. Lian F, Li Y, Bhuiyan M, Sarkar FH (1999) p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer 33: 125-131. (Pubitemid 29269998)
127. http://www.drugbank.ca/drugs/DB02546. (accessed in November 10, 2013).
128. Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, et al. (2010) The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9: 3210-3220.
129. http://www.drugbank.ca/drugs/DB04845. (accessed in November 10, 2013).
130. Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, et al. (2012) A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol 70: 583-590.
131. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, et al. (2006) A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 24: 441-446. (Pubitemid 43876081)
132. http://www.drugbank.ca/drugs/DB05109. (accessed in November 10, 2013).
133. Massuti B, Cobo M, Camps C, Domine M, Provencio M, et al. (2012) Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer 76: 354-361.
134. http://www.drugbank.ca/drugs/DB06772. (accessed in November 10, 2013).
135. Villanueva C, Awada A, Campone M, Machiels JP, Besse T, et al. (2011) A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer 47: 1037-1045.